Lundbeck Reports Phase IV THRIVE Trial Headline Results
Lundbeck announced headline results from the Phase IV THRIVE trial evaluating VYEPTI (eptinezumab) in patients with an inadequate response to prior CGRP-targeting preventive therapy.
Lundbeck announced headline results from the Phase IV THRIVE trial evaluating VYEPTI (eptinezumab) in patients with an inadequate response to prior CGRP-targeting preventive therapy.